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Objectives: To assess the effectiveness, tolerability and maintenance of vildaglip-
tin in type 2 diabetes (T2D) patients under real-life conditions in France, requested 
by the French Health Technology Agency. MethOds: A representative sample of 
T2D patients initiating a treatment with vildagliptin was enrolled in a 2 years fol-
low-up observational cohort in 2010 by a national sample of endocrinologists and 
general practitioners. Results: A total of 482 GPs and 84 endocrinologists included 
1,700 patients. 60% were males, mean age= 63 (±9) years, mean disease duration= 7 
(±6.5) years. Follow up visits were available for 96.3%, 90.7%, 86.5% and 81.8% of 
patients at respectively 6, 12 18 and 24 months. Mean HbA1c level decreased from 
7.8% (sd= 1.3) before vildagliptin prescription to 7.0% (sd= 1.0) 0 to 6 months after 
vildagliptin initiation and remained stable thereafter: 7.0% (sd= 1.0), 7.0% (sd= 0.9) 
and 7.0% (sd= 1.0) 6 to 12 months, 12 to 18 months and 18 to 24 months after vilda-
gliptin initiation. The percentages of patients with alanine and/or aspartate ami-
notransferase above 120 UI were 0.5% before vildagliptin prescription and 0.3%, 0.5%, 
0.1%, 0.0% at 0-6 months, 6-12 months, 12-18 months and 18-24 months after vilda-
gliptin prescription. The mean glomerular filtration rate (MDRD formula) was 82.0 
ml/minute before vildagliptin prescription and 82.4, 84.1, and 83.6 and 82.8, at 0-6 
months, 6-12 months, 12-18 months and 18-24 months after vildagliptin prescrip-
tion. The incidence of severe hypoglycemia (requiring third party assistance) has 
been estimated at 0.30/100 vildagliptin treated patients years (CI95%= [0.15,0.55]). 
All occurred in patients also treated with insulin and/or sulfamide The proportion 
of patients treated with vildagliptin remained high over the course of the study: 
96.5% (CI95%[95.6,97.4]) after 6 months, 92.5% (CI95%= [91.2%,93.8%]) after one year 
and 88.8% (CI95%= [87.2%,90.4%]) after 2 years. cOnclusiOns: Vildagliptin showed 
sustained effectiveness in terms of reduction in HbA1c over 24 months, with a low 
incidence of hypoglycemia.
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Objectives: To compare clinical outcomes and the health care costs across 
two cohorts of uncontrolled diabetic patients who initiated treatment with 
Sulfonamides or Thiazolidinediones (SU/TZD) or Dipeptidyl Peptidase 4 (DPP-4) 
Inhibitors in a clinical practice setting. MethOds: A retrospective analysis using a 
large administrative database and a clinical registry containing laboratory results 
of three Italian Local Health Units was performed. The index-period ranged from 
July, 2008 and June, 2010. Patients were treatment naïve to SU/TZD or to DPP-4, 
but already treated with other oral antidiabetic agents. Demographics, concomi-
tant therapies, Charlson comorbidity index, glycemic and lipid control level and 
previous hospitalizations were assessed at baseline. Adherence was measured 
by Medication Possession Ratio (MPR). We calculated unadjusted rates and used a 
Poisson regression model to estimate risk ratios for diabetes-related hospitaliza-
tions occurred during the 18-months follow-up period. Total annual costs included 
all the pharmacological treatments and the direct costs due to hospitalizations 
and outpatient services. Results: We identified 1384 patients treated with SU/
TZD and 199 treated with DPP-4. DPP-4 patients were significantly younger (mean 
age 59.2 years and 65.0 years; p< 0.001) and with less previous hospital discharges 
for diabetes-related diseases. Baseline mean HbA1c was 8.1% for SU/TZD and 
8.2% for DPP-4 patients. DPP-4 naïve resulted more adherent (MPR≥ 80%) than SU/
TZD naïve (70.9% and 55.8%; p< 0.001). The SU/TZD group showed a significant 
increased risk of diabetes-related hospitalizations (unadjusted rate was 9,17 vs 
3,47 per 100 person-years, p= 0.002; adjusted incidence rate ratio 1.83; p= 0.028). 
The higher hospitalization rate resulted in higher total annual direct costs per 
patient (€ 2.719 vs € 2.462 of those treated with DPP-4). cOnclusiOns: Results 
indicate that uncontrolled diabetic patients who initiated treatment with DPP-4, 
compared with those initiating with SU/TZD, are associated with a reduced risk 
of diabetes-related hospitalizations and consequently with a lower overall total 
annual cost per patient.
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Objectives: To describe epidemiological characteristics among adrenal insufficiency 
(AI) patients and describe the prevalence of risk factors in primary and secondary AI 
(PAI; SAI) and an unmatched, non-AI population. These analyses explore metabolic 
morbidity in AI, which literature suggests may be associated to a non-physiological 
cortisol profile. MethOds: Initial aggregated data from the FARSITE database were 
analysed. The prevalence of risk factors was evaluated, including hypertension, BMI, 
diabetes and depression, and compared across PAI, SAI and non-AI populations. 
Characteristics of non-AI patients were not matched with AI patients. Results: A 
total of 261,638 patients were included; 62 PAI and 191 SAI. Prevalence of hypertension 
was 32% in PAI, 22% in SAI and 13% non-AI. 26% of hypertension in SAI was not on 
target according to QOF criteria (14% non-AI; 10% PAI). Hypercholesterolemia occurred 
in 13% of PAI and 6% of SAI patients (3% non-AI). Among SAI patients, 69% were over-
weight (BMI> 25) or obese (BMI> 30) (63% PAI; 39% non-AI). Diabetes (Type 1 and 2) was 
prevalent in 13% of PAI and 10% of SAI (5% non-AI), with HbA1c not controlled accord-
ing to QOF criteria in 75% of PAI and 74% of SAI patients. Psychological risk factors 
were more prevalent among AI patients; 24% of PAI and 14% of SAI patients recently 
received anti-anxiety/depression treatment (6% non-AI). Hypnotics were recently 
prescribed to 6% of SAI patients (1% non-AI; PAI not reported). Bisphosphonates are 
used by 21% of PAI and 8% of SAI patients (2% non-AI). The hospital admission rate 
was 3% for SAI patients (1% non-AI; PAI not reported). cOnclusiOns: The preva-
lence of metabolic and other risk factors is considerably higher among AI patients 
indirect pairwise odds ratios (OR) were obtained. The study used Bayesian Analysis 
Using Gibbs Sampling in Windows (WinBUGS) version 1.4.3. and Monte Carlo 
Simulations to conduct a multiple treatment comparison. Results are reported in 
OR with 95% credible intervals (CI) and the median of ranking. Results: There were 
a total of 10 studies with 23 treatment arms, representing 2,885 subjects enrolled, 
that were included in the analysis. The results from fix effects model indicated 
that duloxetine, pregabalin, gabapentin, and co-administration of duloxetine and 
gabapentin were significantly better than amitriptyline (OR= 3.22[95%CI, 1.54-7.17], 
OR = 2.53[95%CI, 1.11-5.94], OR = 4.00[95%CI, 1.33-11.69], OR = 2.86[95%CI, 1.09-7.48], 
respectively). The results from random effects model suggested that only duloxetine 
and pregabalin were significantly better than placebo (OR = 2.61[95%CI, 1.37-4.95] 
and OR = 1.97[95%CI, 1.01-3.62], respectively). There was no significant difference 
between amitriptyline and placebo in either fixed or random effects models. With 
regard to the median ranking, gabapentin was ranked first, followed by duloxetine, 
co-administration of duloxetine and gabapentin, pregabalin, placebo, and amitrip-
tyline from the fix effects model. cOnclusiOns: Treatment of PDPN with amitrip-
tyline does not appear to be significantly different from placebo. Duloxetine and 
pregabalin appear to be better than both amitriptyline and placebo.
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Objectives: The GALATA study was the first observational study on DPP-4 inhibitors in 
Turkey and aimed to evaluate the efficacy, safety and tolerability of vildagliptin and met-
formin combination (VMc) in patients with type 2 diabetes mellitus (T2DM). MethOds: 
A total of 648 of the 682 screened T2DM outpatients (age > 18 years) on VMc for at least 
4 weeks prior to enrollment were included in this 24-week, multicenter, observational 
study. Results: Of the 648 patients, 382 (59.0%) were female. The mean (standard devi-
ation-SD-) age was 55.2 (10.2) years, the mean (SD) T2DM duration was 4.8 (5.2) years and 
220 (34.0%) patients had T2DM for more than 5 years. Patients were followed for median 
(inter-quartile range-IQR-) 184.0 (74.0) days at median (IQR) 4.0 (2.0) visits. Median vilda-
gliptin and metformin doses were 100.0 mg and 2000 mg, respectively. HbA1c decreased 
from 7.8% to 7.0% (p< 0.001). A similar reduction in HbA1c from 7.6% to 7.1% was also seen 
in elderly patients (> 65 years, 18.1% of patients) (p< 0.001). The proportion of patients 
with HbA1c ≤ 6.5% increased from 13.3% to 42.7% (p< 0.001) and those with HbA1c ≤ 7.0% 
increased from 26.6% to 65.3% (p< 0.001). Mean fasting plasma glucose (FPG) decreased 
from 153.1 mg/dL to 136.5 mg/dL (p< 0.001), whereas mean post-prandial plasma glucose 
(PPG) decreased from 217.6 mg/dL to 182.1 mg/dL (p< 0.001). Eighty (12.3%) patients expe-
rienced 122 adverse events (AEs) including 3 serious AEs; 2 SAEs were not suspected to 
be related to VMc. AEs were mostly (94.3%) mild or moderate in severity and no action 
was taken for 44.3% of them; 76.2% of AEs resolved during follow-up. cOnclusiOns: 
The results of the GALATA study suggested that VMc significantly decreased HbA1c, FPG 
and PPG, achieved glycemic control targets even in elderly patients and demonstrated 
good overall safety and tolerability in T2DM patients.
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Objectives: Collect randomized clinical evidence on the efficacy and safety of anti-
diabetic agents used in dual or triple therapy or add-on to insulin to provide a qualita-
tive overview of the available evidence and undertake a meta-analysis. MethOds: 
A SLR was conducted in line with NICE guidelines to identify randomised controlled 
trials assessing agents received in combination with metformin (MET), a sulphony-
lurea (SU), MET+SU, MET+pioglitazone, or insulin. Interventions of interest included 
SGLT-2 inhibitors (canagliflozin and dapagliflozin), sulphonylureas, pioglitazone, 
DDP-4 inhibitors, GLP-1 analogues and insulin. Electronic searches were undertaken 
using Medline, Medline-in-process, Embase, and the Cochrane Library and supple-
mented with hand searches. An ad hoc search was conducted to identify the most 
recent data at 104 weeks. Results: A total of 159 clinical trials met inclusion criteria. 
The frequency of studies by background therapy was as follows: MET (38%), mixed 
(trials containing treatment arms with different background therapies; 25%), insulin 
(21%), MET+SU (9%), and SU alone (8%). One study (assessing canagliflozin) featured 
a background of MET+pioglitazone. Studies varied in terms of treatment duration (12 
to 104 weeks), presence and duration of run-in periods (57% studies with run-in, from 
0.7 to 18 weeks), HbA1c eligibility criteria (minimum from 6% to 7%), body mass index 
(BMI; 37 studies focused on overweight and obese patients, two studies focused on 
obese patients) and age for inclusion (from ≥ 18 to ≤ 85 years). cOnclusiOns: The 
outcome of this SLR will serve as input-data in a meta-analysis, to assess relative 
efficacy of T2DM treatments in different background therapy settings.
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